Clinical trials: Plasmodium Falciparum Malaria
Uncomplicated Plasmodium Falciparum Malaria
Triple Artemisinin-based Combination Therapy for Delaying Drug Resistance Development - a Randomized Clinical Trial
Background: Artemisinin resistance has emerged in parts of Southeast Asia, and there are reports in Africa of reduced susceptibility of Plasmodium falciparum parasites against artemisinin-based combination therapy (ACT).
- Trial name
- 3ACT (NCT05764746)
- Testing
- Artemether-lumefantrine and Amodiaquine Drug Combination, Artemether-lumefantrine then Artesunate amodiaquine, Artemether-lumefantrine
- Where
- 2 sites in Tanzania
- Volunteers
- 384 people
- Sponsor
- Muhimbili University of Health and Allied Sciences
Plasmodium Falciparum Malaria
Artemisinin-resistant Malaria in Cambodia
Background: Artemisinin-based combination therapies (ACTs) are the first-line treatments for malaria. ACTs are highly effective, but malaria caused by the Plasmodium falciparum parasite is becoming resistant to some ACTs.
- Trial name
- NCT01736319
- Where
- Cambodia
- Volunteers
- 561 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria
Efficacy of Artesunate + Amodiaquine Four Years After Its Introduction in Zanzibar
The purpose of this study is to assess the efficacy of artesuante + amodiaquine four years after its introduction as first line treatment for uncomplicated childhood malaria in Zanzibar.
- Trial name
- NCT00465257
- Testing
- artesunate + amodiaquine
- Where
- Tanzania
- Volunteers
- 110 people
- Sponsor
- Karolinska University Hospital
Plasmodium Falciparum Malaria
A Challenge Study to Assess the Protective Efficacy of Two Malaria Vaccine Candidates
This study aims to assess the safety and effectiveness of four new candidate malaria vaccines; ChAd63 CS, ChAd63 ME-TRAP, MVA CS \& MVA ME-TRAP.
- Trial name
- VAC045 (NCT01623557)
- Testing
- ChAd63-MVA CS, ChAd63-MVA ME-TRAP, Controlled Human Malaria Infection Administered by Mosquito Bite
- Where
- 3 sites in United Kingdom
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Plasmodium Falciparum Infection
A Systems Biology Approach to Malaria Immunity
This is a phase I study that will assess the acquisition of immunity to Pf malaria over the course of 5 sequential Controlled Human Malaria Infections (CHMI) over 2-4 years, in 10 healthy adult participants.
- Trial name
- NCT03014258
- Testing
- NF54 P. falciparum malaria challenge
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Uncomplicated Malaria
Amodiaquine+Artesunate for Uncomplicated Malaria Treatment
This is a phase IV one-arm study aiming at recruiting 50 patients to assess the efficacy of AQ+AS in patients with a positive RDT diagnosis of malaria in Nanoro, Burkina Faso.
- Trial name
- ASAQ-MAL (NCT01213433)
- Testing
- Artesunate-Amodiaquine
- Where
- Burkina Faso
- Volunteers
- 150 people
- Sponsor
- Centre Muraz
Severe Malaria, Thrombocytopenia
Platelet-Directed Whole Blood Transfusion Strategy for Malaria
Open-label randomized controlled trial to test the effectiveness of whole blood transfusion for improving survival in children with severe malaria complicated by thrombocytopenia.
- Trial name
- PLATFORM (NCT05711485)
- Testing
- Whole blood transfusion
- Where
- 2 sites in United States, Zambia
- Volunteers
- 132 people
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Plasmodium Vivax Malaria Without Complication, Plasmodium Falciparum Malaria (Uncomplicated)
Ethiopian Antimalarial Therapeutic Efficacy Study 2026
Background: The WHO recommends monitoring the efficacy of antimalarial drugs at least once every two years after implementation.
- Trial name
- TES2026 (NCT07840898)
- Testing
- Artemether-Lumefantrine + Primaquine and Chloroquine + Primaquine
- Where
- Ethiopia
- Volunteers
- 1,200 people
- Sponsor
- Ethiopian Public Health Institute
Malaria
Fosmidomycin and Azithromycin for Acute Uncomplicated Plasmodium Falciparum Malaria (P. Malaria) in Adults
The aim of this study is to evaluate the role of azithromycin as a possible combination partner for fosmidomycin to protect it from its susceptibility to recrudescent infections when used as monotherapy for acute Plasmodium…
- Trial name
- JP011 (NCT01464125)
- Testing
- Fosmidomycin, Azithromycin
- Where
- Thailand
- Volunteers
- 43 people
- Sponsor
- Jomaa Pharma GmbH
Malaria, Malaria, Falciparum
Efficacy of Combined PEV3A Virosomal Vaccine and FP9-MVA ME-TRAP Prime Boost Regimen
The purpose of this study is to test three candidate malaria vaccines in new combinations to assess their efficacy at preventing malaria infection and triggering immune responses against malaria.
- Trial name
- NCT00408668
- Testing
- PEV3A, FP9 ME-TRAP, MVA ME-TRAP
- Where
- United Kingdom
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Severe Malaria, Malaria
Severe Malaria and Anti-malarial Drug Resistance in Cambodia
This study, conducted by the National Center for Malaria Control of Cambodia's Ministry of Health, the Guangzhou University of Traditional Chinese Medicine in the People's Republic of China, and the U.S.
- Conditions
- Severe Malaria, Malaria, Antimalarial Drug Resistance
- Trial name
- NCT00341003
- Where
- Cambodia
- Volunteers
- 2,090 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria, Asymptomatic Malaria
OPTIMAL LEAP: Optimizing Dihydroartemisinin-Piperaquine IPTsc Intervals to Advance Learning, Executive Function, Attendance, and Antimalarial Resistance Surveillance in Kenyan Schoolchildren
Malaria remains a major cause of illness among school-aged children in sub-Saharan Africa, many of whom carry asymptomatic Plasmodium falciparum infections that may contribute to anemia, inflammation, school absenteeism, and…
- Conditions
- Malaria, Asymptomatic Malaria, Intermittent Preventive Treatment
- Trial name
- Optimal LEAP (NCT07798583)
- Testing
- Monthly DP, Quarterly DP
- Volunteers
- 1,500 people, healthy volunteers welcome
- Sponsor
- Indiana University
Plasmodium Falciparum, Malaria, Falciparum
Safety, Tolerability, Pharmacokinetics and Efficacy of ARCO
Phase IV, single center, 2 arms randomized controlled, open label study. Study will be conducted over a period of 42 days to determine the safety, tolerability, pharmacokinetics and efficacy of ARCO.
- Trial name
- NCT01930331
- Testing
- artemisinin/naphthoquine, dihydroartemisinin/piperaquine phosphate
- Where
- Tanzania
- Volunteers
- 60 people
- Sponsor
- Ifakara Health Institute
Malaria
A Challenge Study to Assess the Safety, Immunogenicity and Efficacy of a Malaria Vaccine Candidate
This is an open-label, multi-centre Phase I/IIa dose escalation blood-stage malaria CHMI trial to assess the safety, immunogenicity and efficacy of the candidate malaria vaccine RH5.1/AS01.
- Trial name
- NCT02927145
- Testing
- RH5.1/ ASO1
- Where
- 2 sites in United Kingdom
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Malaria, Pregnancy
Pharmacokinetics of Mefloquine-Artesunate in Pregnant Women With Uncomplicated Plasmodium Falciparum Infection
Artemisinin-based combination therapies (ACTs) are now the treatment of choice for malaria in non-pregnant individuals living in areas with established chloroquine resistance; they have been shown to be both safe and highly…
- Trial name
- NCT01082718
- Testing
- Mefloquine Artesunate
- Sponsor
- Centers for Disease Control and Prevention
Malaria
Sanaria PfSPZ Challenge With Pyrimethamine or Chloroquine Chemoprophylaxis Vaccination (PfSPZ-CVac Approach): A Randomized Double Blind Placebo Controlled Phase I/II Trial to Determine Safety and Protective Efficacy Against Natural Plasmodium Falcipa...
Background: Malaria remains a major global health problem. Malaria is spread by the bite of mosquitos. Africa is the region of the world where most people get malaria. Sanaria PfSPZ Challenge is a malaria vaccine.
- Trial name
- NCT03952650
- Testing
- Chloroquine Phosphate, PfSPZ Challenge, Pyrimethamine
- Where
- Mali
- Volunteers
- 252 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria,Falciparum
Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of MMV371 LAI in Healthy Participants
This four-cohort, first-in-human, healthy participant study aims to assess the test medicine's safety and tolerability, including injection site reactions and how it is taken up by the body when given as a single dose.
- Trial name
- NCT06558643
- Testing
- MMV371 LAI
- Where
- United Kingdom
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Medicines for Malaria Venture
Uncomplicated Falciparum Malaria
Azithromycin Combination Therapy for the Treatment of Uncomplicated Falciparum Malaria in Bangladesh
The purpose of this study is to investigate the efficacy of azithromycin combination therapy with artesunate for the treatment of uncomplicated falciparum malaria in Bangladesh.
- Trial name
- NCT00356005
- Testing
- azithromycin plus artesunate, Artesunate
- Where
- Bangladesh
- Volunteers
- 228 people
- Sponsor
- Medical University of Vienna
Malaria,Falciparum
Study of the Transmission-Blocking Vaccine Pfs230D1-EPA/Matrix-M Against Malaria in Adults in Mali
Background: Researchers are trying to develop a vaccine that will safely reduce the spread of malaria in the community by preventing mosquitos from carrying malaria from person to person.
- Trial name
- NCT05135273
- Testing
- Pfs230D1-EPA/Matrix-M Vaccine, Verorab Rabies Vaccine
- Where
- Mali
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Falciparum Malaria
Safety and Efficacy Study of Adjunctive Rosiglitazone in the Treatment of Uncomplicated Falciparum Malaria
The purpose of this study is to examine the safety, tolerability, and efficacy of adjunctive rosiglitazone in the treatment of uncomplicated P.falciparum malaria.
- Trial name
- NCT00149383
- Testing
- Rosiglitazone
- Where
- Thailand
- Volunteers
- 140 people
- Sponsor
- Mahidol University